Latest News

Squamous Cell Lung Cancer Cells Are Sugar-dependent

Squamous Cell Lung Cancer Cells Are Sugar-dependent

Squamous cell lung cancers, a form of NSCLC, are glucose-dependent, while adenocarcinoma NSCLC tumors are largely glucose-independent.

Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-associated Survival

Lung Cancer Radiotherapy Might Improve Immune Checkpoint Blockade-associated Survival

Researchers call for additional clinical trials investigating radiotherapy followed by immune checkpoint blockade for patients with NSCLC.

Rituximab for DLBCL May Double Risk of Subsequent AML

Rituximab for DLBCL May Double Risk of Subsequent AML

Rituximab's mechanism of action may reduce immune surveillance, allowing for the proliferation of cancer cells and infectious agents.

FOLFOXIRI-Bev May Improve Surgical Resection Rate in Colorectal Cancer

FOLFOXIRI-Bev May Improve Surgical Resection Rate in Colorectal Cancer

FOLFOXIRI-Bev yields "rapid and deep cytoreduction" that can improve patients' opportunities for metastatic colorectal tumor resection.

HPV, p16 Status May Affect Prognosis in HNSCC

HPV, p16 Status May Affect Prognosis in HNSCC

Among patients suffering post-radiation or chemoradiation locoregional HNSCC recurrence, those with HPV-positive disease may have better survival rates.

Young Patients With CLL At Risk for Secondary Cancers

Young Patients With CLL At Risk for Secondary Cancers

Patients with chronic lymphocytic leukemia younger than age 55 are at an increased risk for multiple types of secondary cancers for up to 15 years after diagnosis.

Ibrutinib Provides Long-term Benefits for Patients With CLL

Ibrutinib Provides Long-term Benefits for Patients With CLL

Ibrutinib provides long term survival benefits to patients with chronic lymphocytic leukemia regardless of cytogenetic risk factors.

Durable PFS With Fludarabine, Rituximab, and Lenalidomide in CLL

Durable PFS With Fludarabine, Rituximab, and Lenalidomide in CLL

Fludarabine and rituximab plus lenalidomide results in durable prolonged PFS compared with FR or FR plus cyclophosphamide among patients with untreated chronic lymphocytic leukemia.

FDA Grants First Tissue/Site Agnostic Indication to Pembrolizumab

FDA Grants First Tissue/Site Agnostic Indication to Pembrolizumab

The FDA has granted accelerated approval for the agency's first tissue/site agnostic indication to pembrolizumab.

Centers for Medicare and Medicaid Services Working To Address Challenges in the Oncology Care Model

Centers for Medicare and Medicaid Services Working To Address Challenges in the Oncology Care Model

CMS is working to determine if an episode-based payment model will work in oncology by using information from the 190 practices and 16 commercial payers who are currently participating in OCM.

Texting To Monitor Adherence and Adverse Events in Breast Cancer

Texting To Monitor Adherence and Adverse Events in Breast Cancer

In this study, researchers developed a strategy to monitor adherence and AEs in real-time using bidirectional texting via BETA-Text.

Neoadjuvant Nivolumab Shows Efficacy in Non-small Cell Lung Cancer

Neoadjuvant Nivolumab Shows Efficacy in Non-small Cell Lung Cancer

Neoadjuvant nivolumab is safe and provides a comparable pathologic response to that with cisplatin-based neoadjuvant chemotherapy in resectable non-small cell lung cancer.

Non-small Cell Lung Cancer: Neutrophil-lymphocyte Ratio Predicts Overall Survival

Non-small Cell Lung Cancer: Neutrophil-lymphocyte Ratio Predicts Overall Survival

The prognostic marker, which was evaluated among patients with stage III NSCLC, held after adjusting for variables including chemoradiation approach and performance status.

Liquid Biopsy Identifies EGFR-TKI Resistance Heterogeneity in Lung Cancer

Liquid Biopsy Identifies EGFR-TKI Resistance Heterogeneity in Lung Cancer

A liquid biopsy analysis shows inter- and intra-patient heterogeneity of EGFR resistance mutations among patients with lung adenocarcinoma who received EGFR-directed TKI therapy.

Third-line TKI Increases Non-relapse Mortality After Allo-HSCT in CML

Third-line TKI Increases Non-relapse Mortality After Allo-HSCT in CML

Multiple lines of TKI therapy are associated with higher NRM rates among patients with chronic myelogenous leukemia who undergo allo-HSCT.

Factors Associated With Hospice Enrollment Among Patients With Hematologic Cancers

Factors Associated With Hospice Enrollment Among Patients With Hematologic Cancers

Availability of important services and adequacy of care are among the factors explaining low numbers of patients with hematologic cancers being referred for hospice care.

Cediranib Prolongs Progression-free Survival in Alveolar Soft Part Sarcoma

Cediranib Prolongs Progression-free Survival in Alveolar Soft Part Sarcoma

Data suggest that cediranib-treatment of ASPS results in a substantial reduction in tumor burden and prolonged PFS.

Regorafenib Clinically Active in Ewing Sarcoma

Regorafenib Clinically Active in Ewing Sarcoma

SARC024 study met its primary endpoint for patients with Ewing sarcoma, and enrollment is ongoing for the liposarcoma and osteosarcoma cohorts.

Pazopanib Active in Malignant/Dedifferentiated SFT

Pazopanib Active in Malignant/Dedifferentiated SFT

Pazopanib showed antitumor efficacy among patients with unresectable or metastatic malignant/dedifferentiated soft fibrous tumors.

Donor KIR3DL1, HLA-B Subtypes Associated With AML HCT Outcomes

Donor KIR3DL1, HLA-B Subtypes Associated With AML HCT Outcomes

KIR3DL1 and HLA-B subtypes mediate NK cell activity against acute myelogenous leukemia and are associated with relapse and mortality after allogeneic hematopoietic cell transplantation.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters